Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b Double-blind Study to Assess the Safety, Tolerability and Preliminary Efficacy of Intra-articular Administration of Resiniferatoxin Versus Placebo for the Treatment of Pain Due to Moderate to Severe Osteoarthritis of the Knee

Next Previous
Trial Profile

Phase 1b Double-blind Study to Assess the Safety, Tolerability and Preliminary Efficacy of Intra-articular Administration of Resiniferatoxin Versus Placebo for the Treatment of Pain Due to Moderate to Severe Osteoarthritis of the Knee

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Resiniferatoxin (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Sponsors Sorrento Therapeutics

Most Recent Events

  • 07 Sep 2023 According to a Sorrento Therapeutics media release, the company has completed the one-year follow up for the last patient dosed in February 2021.
  • 22 May 2023 According to a Sorrento Therapeutics media release, resiniferatoxin received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pain associated with osteoarthritis (OA) of the knee, based on data from phase I and phase II studies.
  • 26 Sep 2022 According to a Sorrento Therapeutics media release, the phase 2 study NCT04885972 was conducted following the analysis of the positive observations from this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top